P450-BM3 variants with improved activity
Granted: March 22, 2022
Patent Number:
11279917
The present invention provides improved P450-BM3 variants with improved activity. In some embodiments, the P450-BM3 variants exhibit improved activity over a wide range of substrates.
Human alpha-galactosidase variants
Granted: March 22, 2022
Patent Number:
11278600
The present invention provides engineered human alpha-galactosidase polypeptides and compositions thereof. The engineered human alpha-galactosidase polypeptides have been optimized to provide improved stability under both acidic (pH<4.5) and basic (pH>7) conditions. The invention also relates to the use of the compositions comprising the engineered human alpha-galactosidase polypeptides for therapeutic purposes.
Engineered deoxyribose-phosphate aldolases
Granted: March 15, 2022
Patent Number:
11274286
The present invention provides engineered deoxyribose-phosphate aldolase polypeptides useful under industrial process conditions for the production of pharmaceutical and fine chemical compounds.
T7 RNA polymerase variants
Granted: February 1, 2022
Patent Number:
11236312
The present invention provides engineered RNA polymerase variants and compositions comprising these variants. The present invention further provides engineered T7 RNA polymerase variants and compositions comprising these variants. These variants have been evolved for selective incorporation of the m7G(5?)ppp(5?)m7G cap analog over GTP at the initiation of in vitro transcription. The present invention also provides methods for selective capping of RNA transcripts.
T7 RNA polymerase variants
Granted: February 1, 2022
Patent Number:
11236311
The present invention provides engineered RNA polymerase variants and compositions comprising these variants. The present invention further provides engineered T7 RNA polymerase variants and compositions comprising these variants. These variants have been evolved for selective incorporation of the m7G(5?)ppp(5?)m7G cap analog over GTP at the initiation of in vitro transcription. The present invention also provides methods for selective capping of RNA transcripts.
Ketoreductase polypeptides for the synthesis of chiral compounds
Granted: February 1, 2022
Patent Number:
11236308
The present disclosure provides engineered ketoreductase enzymes having improved properties as compared to a naturally occurring wild-type ketoreductase enzyme. Also provided are polynucleotides encoding the engineered ketoreductase enzymes, host cells capable of expressing the engineered ketoreductase enzymes, and methods of using the engineered ketoreductase enzymes to synthesize a variety of chiral compounds.
Penicillin-G acylases
Granted: January 4, 2022
Patent Number:
11214786
The present invention provides engineered penicillin G acylase (PGA) enzymes having improved properties, polynucleotides encoding such enzymes, compositions including the enzymes, and methods of using the enzymes.
Engineered phenylalanine ammonia lyase polypeptides
Granted: December 14, 2021
Patent Number:
11198861
The present invention provides engineered phenylalanine ammonia lyase (PAL) polypeptides and compositions thereof, as well as polynucleotides encoding the engineered phenylalanine ammonia lyase (PAL) polypeptides. Methods for producing PAL enzymes are also provided. In some embodiments, the engineered PAL polypeptides are optimized to provide enhanced catalytic activities that are useful under industrial process conditions for the production of pharmaceutical compounds.
Processes using amino acid dehydrogenases and ketoreductase-based cofactor regenerating system
Granted: December 7, 2021
Patent Number:
11193157
The present disclosure relates to the use of an amino acid dehydrogenase in combination with a cofactor regenerating system comprising a ketoreductase. In particular embodiments, the process can be used to prepare L-tert-leucine using a leucine dehydrogenase.
Variant penicillin-G acylases
Granted: November 23, 2021
Patent Number:
11180747
The present disclosure relates to engineered penicillin G acylase (PGA) enzymes having improved properties, polynucleotides encoding such enzymes, compositions including the enzymes, and methods of using the enzymes.
Engineered purine nucleoside phosphorylase variant enzymes
Granted: November 2, 2021
Patent Number:
11162105
The present invention provides engineered purine nucleoside phosphorylase (PNP) enzymes, polypeptides having PNP activity, and polynucleotides encoding these enzymes, as well as vectors and host cells comprising these polynucleotides and polypeptides. Methods for producing PNP enzymes are also provided. The present invention further provides compositions comprising the PNP enzymes and methods of using the engineered PNP enzymes. The present invention finds particular use in the…
Engineered phenylalanine ammonia lyase polypeptides
Granted: October 5, 2021
Patent Number:
11136571
The present invention provides engineered phenylalanine ammonia-lyase (PAL) polypeptides and compositions thereof, as well as polynucleotides encoding the engineered phenylalanine ammonia-lyase (PAL) polypeptides.
Engineered phenylalanine ammonia lyase polypeptides
Granted: September 28, 2021
Patent Number:
11130947
The present invention provides engineered phenylalanine ammonia-lyase (PAL) polypeptides and compositions thereof, as well as polynucleotides encoding the engineered phenylalanine ammonia-lyase (PAL) polypeptides.
Engineered transaminase polypeptides for industrial biocatalysis
Granted: August 24, 2021
Patent Number:
11098292
The present disclosure provides engineered transaminase polypeptides useful for the synthesis of chiral amine compounds under industrially relevant conditions. The disclosure also provides polynucleotides encoding the engineered transaminase polypeptides, host cells capable of expressing the engineered transaminases, and methods of using the engineered transaminases for the production of chiral amine compounds.
Biocatalysts and methods for synthesizing derivatives of tryptamine and tryptamine analogs
Granted: August 24, 2021
Patent Number:
11098291
The present disclosure provides engineered transaminase polypeptides for the production of amines, polynucleotides encoding the engineered transaminases, host cells capable of expressing the engineered transaminases, and methods of using the engineered transaminases to prepare compounds useful in the production of active pharmaceutical agents.
Transaminase biocatalysts
Granted: August 3, 2021
Patent Number:
11078505
The present disclosure relates to polypeptides having transaminase activity, polynucleotides encoding the polypeptides, and methods of using the polypeptides.
Ketoreductase polypeptides for the production of azetidinone
Granted: August 3, 2021
Patent Number:
11078466
The present disclosure provides engineered ketoreductase enzymes having improved properties as compared to a naturally occurring wild-type ketoreductase enzyme. Also provided are polynucleotides encoding the engineered ketoreductase enzymes, host cells capable of expressing the engineered ketoreductase enzymes, and methods of using the engineered ketoreductase enzymes to synthesize a variety of chiral compounds.
Engineered DNA polymerase variants
Granted: July 13, 2021
Patent Number:
11060075
The present invention provides engineered DNA polymerase polypeptides and compositions thereof, as well as polynucleotides encoding the engineered DNA polymerase polypeptides. The invention also provides methods for use of the compositions comprising the engineered DNA polymerase polypeptides for diagnostic and other purposes.
Engineered imine reductases and methods for the reductive amination of ketone and amine compounds
Granted: July 13, 2021
Patent Number:
11060072
The present application provides engineered polypeptides having imine reductase activity, polynucleotides encoding the engineered imine reductases, host cells capable of expressing the engineered imine reductases, and methods of using these engineered polypeptides with a range of ketone and amine substrate compounds to prepare secondary and tertiary amine product compounds.
Engineered imine reductases and methods for the reductive amination of ketone and amine compounds
Granted: June 29, 2021
Patent Number:
11046936
The present application provides engineered polypeptides having imine or oxime reductase activity, polynucleotides encoding the engineered polypeptides, host cells capable of expressing the engineered polypeptides, and methods of using these engineered polypeptides with a range of ketone amine substrate compounds to prepare secondary and tertiary amine product compounds.
